Media headlines about Catalyst Pharmaceuticals (NASDAQ:CPRX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.8743112027991 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several equities analysts recently commented on the company. BidaskClub upgraded Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. ValuEngine upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.25.

Shares of Catalyst Pharmaceuticals stock traded down $0.01 during midday trading on Wednesday, hitting $3.22. 482,304 shares of the company were exchanged, compared to its average volume of 714,352. The company has a market capitalization of $328.31 million, a PE ratio of -15.33 and a beta of 1.59. Catalyst Pharmaceuticals has a 52 week low of $2.09 and a 52 week high of $4.51.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). sell-side analysts anticipate that Catalyst Pharmaceuticals will post -0.34 EPS for the current year.

In related news, Director Donald A. Denkhaus bought 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The stock was acquired at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the transaction, the director now directly owns 120,000 shares of the company’s stock, valued at $450,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased a total of 29,000 shares of company stock valued at $106,940 in the last 90 days. 9.30% of the stock is owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with's FREE daily email newsletter.